-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, GemVax & KAEL (hereinafter referred to as GemVax) announced that the results of the company’s active Phase 2 clinical trial of the company’s research therapy GV1001 for the treatment of patients with Alzheimer’s disease were published in the journal Alzheimer's Research & Therapy.
Alzheimer's disease (AD) is the most common neurodegenerative disease in the elderly.
GV1001 is a polypeptide composed of 16 amino acids, which corresponds to the catalytic site fragment of human telomerase reverse transcriptase (TERT).
In a randomized, double-blind, placebo-controlled phase 2 clinical trial, a total of 96 Alzheimer's disease patients received placebo or different doses of GV1001 treatment.
The test results showed that after 24 weeks of treatment, the SIB scores of patients treated with higher doses of GV1001 were significantly improved compared with the placebo group.
▲SIB score changes of patients treated with different doses of GV1001 or placebo, orange is the highest dose GV1001 treatment group, dark blue is the control group (picture source: reference [2])
GemVax has submitted an IND application to the Korean regulatory agency, seeking to initiate a phase 3 clinical trial to test the efficacy of GV1001.
Reference materials:
[1] GemVax's highly promising Phase II Alzheimer's disease clinical trial results targeting telomerase published in prestigious Alzheimer's Research & Therapy' journal.
[2] Seong-Ho Koh, et al.
